Compare Inovio Pharmaceuticals Inc (INO) vs Liquidia Corporation Common Stock (LQDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Liquidia Corporation Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Liquidia Corporation Common Stock trades at $34 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 29.8× Inovio Pharmaceuticals Inc's market cap, and Liquidia Corporation Common Stock is more actively traded (21,111,778 versus 2,985,847). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Liquidia Corporation Common Stock for 0 Days on average.
| INO | LQDA | |
|---|---|---|
Market Cap | $101.95M | $3.04B |
Volume | 2,985,847 | 21,111,778 |
Sector | Health | Health |
52-Week High | $2.60 | $91.03 |
52-Week Low | $0.66 | $22.02 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →
